NCT02933281View on ClinicalTrials.gov

MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

May 14, 2018

Primary Completion Date

September 5, 2021

Study Completion Date

September 5, 2021

Conditions
Tuberculosis
Interventions
BIOLOGICAL

MTBVAC

Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU

BIOLOGICAL

BCG

BCG 5 x 10\^5 CFU

Trial Locations (1)

6850

SATVI: Worcester, Worcester

Sponsors

Collaborators (1)

Biofabri, S.L
All Listed Sponsors
collaborator

Biofabri, S.L

INDUSTRY

collaborator

Universidad de Zaragoza

OTHER

collaborator

South African Tuberculosis Vaccine Initiative

OTHER

lead

International AIDS Vaccine Initiative

NETWORK

NCT02933281 - MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa | Biotech Hunter | Biotech Hunter